Drs. Taghipour, Carome and Wolfe:

This is in response to your November 6, 2019, letter petitioning the Drug Enforcement Administration (DEA) to initiate proceedings for the rescheduling of 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, its optical and geometric isomers, and salts of these isomers (including tramadol) from schedule IV to schedule II of the Controlled Substances Act. The petition substantially complies procedurally with the requirements of 21 CFR § 1308.43 (b) and the DEA is therefore accepting the petition for filing.

If you should have further questions relating to your petition, please feel free to contact Terrence Boos, Ph.D., Section Chief, Drug and Chemical Evaluation Section, at (571) 362-3249.

Sincerely,

Brian Besser
Deputy Assistant Administrator
Diversion Control Division